RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of Christopher H. Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer. Cabell succeeds Oren Cohen, M.D., who was recently appointed Senior Vice President, Clinical Research Strategies.
As Chief Medical and Scientific Officer, Cabell will be responsible for company-wide initiatives that focus on bioethics and the protection of human subjects. In addition, he will be responsible for developing initiatives that bring forward innovations in medicine, science and technology into future business models.
Most recently, Cabell held the position of Global Cardiovascular / Endocrine Therapeutic Group Leader within the Medical and Scientific Services group and provided cardiology expertise for Quintiles Electrocardiogram (ECG) Services. In 2007, Cabell joined Quintiles from the Duke University School of Medicine, where he developed a strong background in clinical research. He held several appointments within the Duke Clinical Research Institute (DCRI), including Co-Chair and Principal Investigator for a Duke/FDA Cardiac Safety partnership to develop a new generation of tools to identify the potential effects of medical devices and drugs on the heart. Also within DCRI, he held appointments as Director of the Echocardiography Core Laboratory, Associate Director of the ECG Core Laboratory and Director of the International Collaboration on Endocarditis. He also was Assistant Professor of Medicine in the Division of Cardiology.
Cabell has authored or co-authored 50 articles for peer-reviewed publications and delivered more than 30 invited lectures. He is a member of several professional organizations, a Fellow of the American College of Cardiology, and a reviewer for a number of medical journals, including the Journal of the American Medical Association. He earned his medical degree and a Master's in Health Science from the Duke University School of Medicine.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com
|SOURCE Quintiles Transnational Corp.|
Copyright©2008 PR Newswire.
All rights reserved